FDA approves Simtriyo for treating ADHD in children and adults
medicalxpress - The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
AI Summary: The FDA granted approval for Simtriyo to treat attention‑deficit/hyperactivity disorder in children and adults, adding a new prescription option to the ADHD toolkit. Regulators highlighted efficacy and safety data supporting the decision; clinicians and patients will now weigh the drug’s profile against existing therapies as rollout and coverage decisions play out.
Related Stories
Drug-induced hibernation shows promise to limit stroke brain injury / 6 wks
FDA backs three psychedelic studies with special commissioner vouchers / 3 months
Mid‑stage Parkinson trial failure halts drug development plans / 2 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 2 months
FDA escalates push to withdraw Amgen’s Tavneos; Amgen updates label / 2 months
Denali drug receives accelerated approval for rare CNS indication / 4 months
FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Medicaid, Cybersecurity, Supply Chain, Eli Lilly and look for the RSS link.
StackHealth Time Machine